Literature DB >> 10205008

Characterization of airway and vascular responses in murine lungs.

H D Held1, C Martin, S Uhlig.   

Abstract

UNLABELLED: 1. We characterized the responses of murine airways and pulmonary vessels to a variety of endogenous mediators in the isolated perfused and ventilated mouse lung (IPL) and compared them with those in precision-cut lung slices. 2. Airways: The EC50 (microM) for contractions of airways in IPL/slices was methacholine (Mch), 6.1/1.5>serotonin, 0.7/2.0>U46619 (TP-receptor agonist), 0.1/0.06>endothelin-1, 0.1/0.05. In the IPL, maximum increase in airway resistance (RL) was 0.6, 0.4, 0.8 and 11 cmH2O s ml(-1), respectively. Adenosine (< or =1 mM), bombesin (< or =100 microM), histamine (< or =10 mM), LTC4 (< or =1 microM), PAF (0.25 microM) and substance P (< or =100 microM) had only weak effects (<5% of Mch) on RL. 3. Vessels: The EC50 (microM) for vasoconstriction in the IPL was LTC4, 0.06>U46619, 0.05<endothelin-1, 0.02. The maximum increase in pulmonary artery pressure (PAP) was 11, 41 and 48 cmH2O, respectively. At 250 nM, the activity of PAF was comparable to that of LTC4. At 100 microM only, substance P caused a largely variable increase in PAP. Serotonin, adenosine, bombesin, histamine and Mch had no or only very small effects on PAP. 4. Hyperresponsiveness: In both the IPL and slices, U46619 in subthreshold concentrations (10 nM) reduced the EC50 to 0.6 microM. In the IPL, U46619 raised the maximum airway response to Mch 5 fold and the maximum PAF-induced vasoconstriction 4 fold. 5.
CONCLUSION: Murine precision-cut lung slices maintain important characteristics of the whole organ. The maximum reagibility of murine airways to endogenous mediators is serotonin<Mch<U46619<ET-1. The reagibility of the murine pulmonary vasculature is serotonin<LTC4 approximately = to PAF<U46619<ET-1. The airway and vessel hyperreactivity induced by U46619 raises the possibility that thromboxane contributes directly to airway hyperresponsiveness in various experimental and clinical settings.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10205008      PMCID: PMC1565872          DOI: 10.1038/sj.bjp.0702394

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  23 in total

1.  Pulmonary vasoconstriction and hypertension in mice with targeted disruption of the endothelial nitric oxide synthase (NOS 3) gene.

Authors:  W Steudel; F Ichinose; P L Huang; W E Hurford; R C Jones; J A Bevan; M C Fishman; W M Zapol
Journal:  Circ Res       Date:  1997-07       Impact factor: 17.367

2.  Videomicroscopy of methacholine-induced contraction of individual airways in precision-cut lung slices.

Authors:  C Martin; S Uhlig; V Ullrich
Journal:  Eur Respir J       Date:  1996-12       Impact factor: 16.671

Review 3.  Thromboxane A2 and related prostaglandins in airways.

Authors:  P Devillier; G Bessard
Journal:  Fundam Clin Pharmacol       Date:  1997       Impact factor: 2.748

4.  Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography.

Authors:  E Hamelmann; J Schwarze; K Takeda; A Oshiba; G L Larsen; C G Irvin; E W Gelfand
Journal:  Am J Respir Crit Care Med       Date:  1997-09       Impact factor: 21.405

5.  Effect of thromboxane A2 inhibitors on allergic pulmonary inflammation in mice.

Authors:  H Shi; A Yokoyama; N Kohno; Y Hirasawa; K Kondo; K Sakai; K Hiwada
Journal:  Eur Respir J       Date:  1998-03       Impact factor: 16.671

6.  Airway responsiveness in transgenic mice overexpressing platelet-activating factor receptor. Roles of thromboxanes and leukotrienes.

Authors:  T Nagase; S Ishii; H Katayama; Y Fukuchi; Y Ouchi; T Shimizu
Journal:  Am J Respir Crit Care Med       Date:  1997-11       Impact factor: 21.405

7.  Hyperventilation induces release of cytokines from perfused mouse lung.

Authors:  A N von Bethmann; F Brasch; R Nüsing; K Vogt; H D Volk; K M Müller; A Wendel; S Uhlig
Journal:  Am J Respir Crit Care Med       Date:  1998-01       Impact factor: 21.405

8.  Responses to leukotriene C4 in the perfused rat lung.

Authors:  V J Iacopino; S Compton; T Fitzpatrick; P Ramwell; J Rose; P Kot
Journal:  J Pharmacol Exp Ther       Date:  1984-06       Impact factor: 4.030

Review 9.  Role of thromboxane A2 synthetase inhibitors in the treatment of patients with bronchial asthma.

Authors:  M Kurosawa
Journal:  Clin Ther       Date:  1995 Jan-Feb       Impact factor: 3.393

10.  Interleukin-12 inhibits antigen-induced airway hyperresponsiveness in mice.

Authors:  J C Kips; G J Brusselle; G F Joos; R A Peleman; J H Tavernier; R R Devos; R A Pauwels
Journal:  Am J Respir Crit Care Med       Date:  1996-02       Impact factor: 21.405

View more
  47 in total

1.  Vascular Dysfunction in Pneumocystis-Associated Pulmonary Hypertension Is Related to Endothelin Response and Adrenomedullin Concentration.

Authors:  Dan W Siemsen; Erin Dobrinen; Soo Han; Kari Chiocchi; Nicole Meissner; Steve D Swain
Journal:  Am J Pathol       Date:  2015-12-11       Impact factor: 4.307

2.  Bioreactor for the long-term culture of lung tissue.

Authors:  Thomas H Petersen; Elizabeth A Calle; Maegen B Colehour; Laura E Niklason
Journal:  Cell Transplant       Date:  2010-11-19       Impact factor: 4.064

3.  Airway contractility in the precision-cut lung slice after cryopreservation.

Authors:  Sonia R Rosner; Sumati Ram-Mohan; Jesus R Paez-Cortez; Tera L Lavoie; Maria L Dowell; Lei Yuan; Xingbin Ai; Alan Fine; William C Aird; Julian Solway; Jeffrey J Fredberg; Ramaswamy Krishnan
Journal:  Am J Respir Cell Mol Biol       Date:  2014-05       Impact factor: 6.914

4.  In vivo genome editing using nuclease-encoding mRNA corrects SP-B deficiency.

Authors:  Azita J Mahiny; Alexander Dewerth; Lauren E Mays; Mohammed Alkhaled; Benedikt Mothes; Emad Malaeksefat; Brigitta Loretz; Jennifer Rottenberger; Darina M Brosch; Philipp Reautschnig; Pacharapan Surapolchai; Franziska Zeyer; Andrea Schams; Melanie Carevic; Martina Bakele; Matthias Griese; Matthias Schwab; Bernd Nürnberg; Sandra Beer-Hammer; Rupert Handgretinger; Dominik Hartl; Claus-Michael Lehr; Michael S D Kormann
Journal:  Nat Biotechnol       Date:  2015-05-18       Impact factor: 54.908

5.  Transient receptor potential vanilloid 4 activation constricts the human bronchus via the release of cysteinyl leukotrienes.

Authors:  M Allen McAlexander; Mark A Luttmann; Gerald E Hunsberger; Bradley J Undem
Journal:  J Pharmacol Exp Ther       Date:  2014-02-06       Impact factor: 4.030

6.  KCNQ (Kv7) potassium channel activators as bronchodilators: combination with a β2-adrenergic agonist enhances relaxation of rat airways.

Authors:  Lioubov I Brueggemann; Jennifer M Haick; Samantha Neuburg; Shawn Tate; Devjit Randhawa; Leanne L Cribbs; Kenneth L Byron
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2014-01-17       Impact factor: 5.464

7.  P2X7R: independent modulation of aquaporin 5 expression in CdCl2-injured alveolar epithelial cells.

Authors:  Julia Heupel; Robert Bläsche; Karl-Philipp Wesslau; Michael Kasper; Kathrin Barth
Journal:  Histochem Cell Biol       Date:  2018-02-03       Impact factor: 4.304

8.  20-HETE mediates ozone-induced, neutrophil-independent airway hyper-responsiveness in mice.

Authors:  Philip R Cooper; A Clementina Mesaros; Jie Zhang; Peter Christmas; Christopher M Stark; Karim Douaidy; Michael A Mittelman; Roy J Soberman; Ian A Blair; Reynold A Panettieri
Journal:  PLoS One       Date:  2010-04-20       Impact factor: 3.240

9.  Cooperation between mast cells and neurons is essential for antigen-mediated bronchoconstriction.

Authors:  Jaime M Cyphert; Martina Kovarova; Irving C Allen; John M Hartney; Dennis L Murphy; Jürgen Wess; Beverly H Koller
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

10.  Human airway contraction and formoterol-induced relaxation is determined by Ca2+ oscillations and Ca2+ sensitivity.

Authors:  Anna-Rebekka Ressmeyer; Yan Bai; Philippe Delmotte; Karl F Uy; Patricia Thistlethwaite; Armando Fraire; Osamu Sato; Mitsuo Ikebe; Michael J Sanderson
Journal:  Am J Respir Cell Mol Biol       Date:  2009-09-18       Impact factor: 6.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.